Literature DB >> 35637286

Assessment of AAV9 distribution and transduction in rats after administration through Intrastriatal, Intracisterna magna and Lumbar Intrathecal routes.

Jayanth Chandran1, Ekram Ahmed Chowdhury2, Michael Perkinton3, Tanguy Jamier3, Daniel Sutton4, Shengjia Wu2, Claire Dobson1, Dhaval K Shah2, Iain Chessell3, Guy M L Meno-Tetang5.   

Abstract

Challenges in obtaining efficient transduction of brain and spinal cord following systemic AAV delivery have led to alternative administration routes being used in clinical trials that directly infuse the virus into the CNS. However, data comparing different direct AAV injections into the brain remain limited making it difficult to choose optimal routes. Here we tested both AAV9-egfp and AAV9-fLuc delivery via intrastriatal (IST), intracisterna magna (ICM) and lumbar intrathecal (LIT) routes in adult rats and assessed vector distribution and transduction in brain, spinal cord and peripheral tissues. We find that IST infusion leads to robust transgene expression in the striatum, thalamus and cortex with lower peripheral tissue transduction and anti-AAV9 capsid titers compared to ICM or LIT. ICM delivery provided strong GFP and luciferase expression across more brain regions than the other routes and similar expression in the spinal cord to LIT injections, which itself largely failed to transduce the rat brain. Our data highlight the strengths and weaknesses of each direct CNS delivery route which will help with future clinical targeting.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2022        PMID: 35637286     DOI: 10.1038/s41434-022-00346-1

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  42 in total

Review 1.  Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic/pharmacodynamic (PK/PD) models.

Authors:  Ekram Ahmed Chowdhury; Guy Meno-Tetang; Hsueh Yuan Chang; Shengjia Wu; Hsien Wei Huang; Tanguy Jamier; Jayanth Chandran; Dhaval K Shah
Journal:  Adv Drug Deliv Rev       Date:  2021-01-21       Impact factor: 15.470

2.  Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates.

Authors:  Steven J Gray; Valerie Matagne; Lavanya Bachaboina; Swati Yadav; Sergio R Ojeda; R Jude Samulski
Journal:  Mol Ther       Date:  2011-04-12       Impact factor: 11.454

3.  Trafficking of adeno-associated virus vectors across a model of the blood-brain barrier; a comparative study of transcytosis and transduction using primary human brain endothelial cells.

Authors:  Steven F Merkel; Allison M Andrews; Evan M Lutton; Dakai Mu; Eloise Hudry; Bradley T Hyman; Casey A Maguire; Servio H Ramirez
Journal:  J Neurochem       Date:  2016-12-15       Impact factor: 5.372

4.  Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy.

Authors:  Jerry R Mendell; Samiah Al-Zaidy; Richard Shell; W Dave Arnold; Louise R Rodino-Klapac; Thomas W Prior; Linda Lowes; Lindsay Alfano; Katherine Berry; Kathleen Church; John T Kissel; Sukumar Nagendran; James L'Italien; Douglas M Sproule; Courtney Wells; Jessica A Cardenas; Marjet D Heitzer; Allan Kaspar; Sarah Corcoran; Lyndsey Braun; Shibi Likhite; Carlos Miranda; Kathrin Meyer; K D Foust; Arthur H M Burghes; Brian K Kaspar
Journal:  N Engl J Med       Date:  2017-11-02       Impact factor: 91.245

Review 5.  Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies.

Authors:  Rachel M Bailey; Alejandra Rozenberg; Steven J Gray
Journal:  Brain Res       Date:  2020-04-11       Impact factor: 3.252

6.  Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates.

Authors:  Darren A Murrey; Bartholomew J Naughton; F Jason Duncan; Aaron S Meadows; Tierra A Ware; Katie J Campbell; William G Bremer; Christopher M Walker; Laurie Goodchild; Brad Bolon; Krista La Perle; Kevin M Flanigan; Kim L McBride; Douglas M McCarty; Haiyan Fu
Journal:  Hum Gene Ther Clin Dev       Date:  2014-04-10       Impact factor: 5.032

7.  Systemic gene delivery following intravenous administration of AAV9 to fetal and neonatal mice and late-gestation nonhuman primates.

Authors:  Citra N Mattar; Andrew M S Wong; Klemens Hoefer; Maria E Alonso-Ferrero; Suzanne M K Buckley; Steven J Howe; Jonathan D Cooper; Simon N Waddington; Jerry K Y Chan; Ahad A Rahim
Journal:  FASEB J       Date:  2015-06-10       Impact factor: 5.191

8.  AAV9 supports wide-scale transduction of the CNS and TDP-43 disease modeling in adult rats.

Authors:  Kasey L Jackson; Robert D Dayton; Ronald L Klein
Journal:  Mol Ther Methods Clin Dev       Date:  2015-09-30       Impact factor: 6.698

9.  Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems.

Authors:  Ken Y Chan; Min J Jang; Bryan B Yoo; Alon Greenbaum; Namita Ravi; Wei-Li Wu; Luis Sánchez-Guardado; Carlos Lois; Sarkis K Mazmanian; Benjamin E Deverman; Viviana Gradinaru
Journal:  Nat Neurosci       Date:  2017-06-26       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.